AQR Capital Management LLC purchased a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 735,566 shares of the company's stock, valued at approximately $16,205,000. AQR Capital Management LLC owned about 0.36% of Cellebrite DI at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. Barclays PLC raised its stake in shares of Cellebrite DI by 29.1% during the third quarter. Barclays PLC now owns 263,657 shares of the company's stock valued at $4,439,000 after acquiring an additional 59,395 shares during the last quarter. Tidal Investments LLC raised its position in Cellebrite DI by 59.3% during the 3rd quarter. Tidal Investments LLC now owns 104,478 shares of the company's stock worth $1,759,000 after purchasing an additional 38,887 shares during the last quarter. Principal Financial Group Inc. acquired a new position in Cellebrite DI during the 3rd quarter worth about $23,402,000. JPMorgan Chase & Co. grew its position in shares of Cellebrite DI by 21.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 427,655 shares of the company's stock valued at $7,202,000 after buying an additional 75,092 shares during the last quarter. Finally, Harbor Capital Advisors Inc. increased its stake in shares of Cellebrite DI by 65.4% in the fourth quarter. Harbor Capital Advisors Inc. now owns 157,671 shares of the company's stock valued at $3,473,000 after buying an additional 62,320 shares during the period. Institutional investors and hedge funds own 45.88% of the company's stock.
Cellebrite DI Trading Up 1.0 %
NASDAQ CLBT traded up $0.20 during mid-day trading on Thursday, hitting $19.28. The company's stock had a trading volume of 894,840 shares, compared to its average volume of 1,424,776. The firm has a market capitalization of $4.62 billion, a price-to-earnings ratio of -13.87, a PEG ratio of 4.27 and a beta of 1.44. The company's 50 day simple moving average is $18.87 and its 200 day simple moving average is $20.20. Cellebrite DI Ltd. has a twelve month low of $10.25 and a twelve month high of $26.30.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. As a group, research analysts forecast that Cellebrite DI Ltd. will post 0.3 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of brokerages have commented on CLBT. Lake Street Capital upped their price target on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, February 14th. JPMorgan Chase & Co. lifted their target price on Cellebrite DI from $24.00 to $28.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $28.00 price target on shares of Cellebrite DI in a research note on Wednesday, April 2nd. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $23.43.
Read Our Latest Stock Analysis on Cellebrite DI
About Cellebrite DI
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Further Reading

Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.